bluuebunny/crossref_metadata_2025 huggingface dataset:
Abstract 426: Identifying a predictive biomarker for chemotherapy (taxane) in patients with metastatic castration resistance prostate cancer
Authors: Rothchild Greg A. , Sandusky George , Temm Constance J. , Albany Costantine
Published: July 2016

In 2015, American Cancer Society predicts that 220,800 men will be diagnosed with prostate cancer (PC). Patients diagnosed with metastatic PC are first treated with androgen deprivation therapies (ADT) in order to lower testosterone to castration levels. Unfortunately, it is only a matter of time before becoming metastatic castration resistant prostate cancer (mCRPC). Subsequent treatments include combined androgen deprivation therapies such as (abiraterone, enzalutamide), immunotherapies, investigational drugs, and/or chemotherapy (docetaxel and cabazitaxel). Individualizing therapy for prostate cancer patients is an overarching goal of research. Currently, no valid practical biomarkers exist that can predict resistance to the taxane in PC. Identifying a marker that predicts taxane sensitivity would delineate patients who would benefit from taxane regimens from those who would suffer from added side-effects without any improved response. Previous studies have confirmed TLE3 is associated with a response to taxane therapy in breast and ovarian cancers. Preclinical studies have also shown that TLR4, RAGE, and HMGB1 confers chemo resistance to docetaxel on PC-3 human PC cells. After obtaining IRB approval (protocol IUCRO-0499), 8 metastatic castration resistant prostate cancer samples and 6 control samples were pulled for this study after scrutinous review of the H&E slides from clinical cases. This study then consisted of investigating the proteins TLE3, TLR4, RAGE, and HMBG1. Immunostaining was performed using the automated immunostainer, Dako FLEX System, and the slides were scanned into the whole slide Aperio Scanscope CS digital imaging system. Computer-assisted morphometric analysis of digital images was then performed using the Aperio ImageScope software. Review of the TLE3 and TLR4 expression in metastatic castration resistance prostate cancer samples showed a difference between the expressions of these two proteins. TLR4 positivity was found to be 43.88% higher than the expression of TLE3. This is suggestive of resistance to docetaxel treatments. Review of the RAGE and HMGB1 expression in metastatic castration resistance prostate cancer samples compared to normal prostate epithelium showed a 32.9% increase in RAGE and 36.6% increase in HMGB1 expression. The findings of this study are suggestive that there is a possible correlation between the overexpression of these protein biomarkers and the patient's response to a specific drug treatment.

Citation Format: Greg A. Rothchild, George Sandusky, Constance J. Temm, Costantine Albany. Identifying a predictive biomarker for chemotherapy (taxane) in patients with metastatic castration resistance prostate cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 426.
Abstract 4266: Reproducible spheroid formation using functionalized hyaluronan 3D scaffolds
Authors: Pannetier Pauline , Louis Fiona , Souguir Zied , Devaux Agathe , Le Cerf Didier , Vannier Jean-Pierre , Demange Elise , Vidal Guillaume
Published: July 2016

Extracellular matrix (ECM) characteristics, including stiffness, porosity, composition and spatial interaction with the surrounding cells and soluble factors are key components for cell growth in a tissue microenvironment. However, poor performance of 2D in vitro systems and animal models demands physiologically relevant well controlled 3D platforms for mechanistic assays, drug resistant phenotypes, new drug efficacy, toxicity assessment.

Technical limitations in the current use of multicellular spheroids prevent their widespread use in cancer research and drug development. Existing systems for spheroid formation require lengthy processing times, and make simple tasks like media exchange, cell retrieval and microscopy analysis challenging. An ideal 3D cell culture system would form spheroids in an in vivo like microenvironment, while being easy to handle and compatible with all analytical methods.

To address this unmet needs, we use a controlled hyaluronic acid-based scaffolds for spheroid formation. We have enriched 2 hyaluronan scaffolds with other components of the ECM such as collagen I, collagen IV, collagen VI, RGDs motif or galactosamine. Functionalised scaffolds overpass the 2D flat culture limitations by recreating cell/cell interactions and cell/matrix interaction to recreate a more physiologically authentic 3D architecture. The 2 functionalized scaffolds recapitulate the microenvironment for Hepatocyte and Adipocyte growth.

Once formed, the spheroids can be cultured long-term, the scaffold is transparent allowing reproducible High Content Screening, the spheroids and the cells can be retrieve, avoiding the technical issues of other 3D systems to retain samples. Moreover, the scaffold is compatible with fluorescence/luminescent kit and immunofluorescent microscopy.

We demonstrated this technology using cell lines, primary cells (adipocytes, hepatocytes). We assayed the spheroids over time using various endpoint spheroid morphology, growth and viability, resistance to anti-cancer drug, relevant cell organization formation and toxicity endpoint.

Thus, this study introduces functionalized HA scaffold for the use of in vitro culture model as that represent native cell environments is ready to ready to use and compatible with HTS and all analytical methods for drug development and compound screening.

Citation Format: Pauline Pannetier, Fiona Louis, Zied Souguir, Agathe Devaux, Didier Le Cerf, Jean-Pierre Vannier, Elise Demange, Guillaume Vidal. Reproducible spheroid formation using functionalized hyaluronan 3D scaffolds. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4266.
Abstract 4289: C-reactive protein and risk of lung cancer: A pooled analysis of 20 prospective cohorts
Authors: Muller David C. , Hodge Allison M. , Severi Gianluca , Cai Qiuyin , Meyer Klaus , Grankvist Kjell , Langhammer Arnulf , Brennan Paul , Johansson Mattias ,   Lung Cancer Cohort Consortium (LC3)
Published: July 2016

Background: Inflammation may have an important role in the etiology of lung cancer, and several studies have reported that C-reactive protein (CRP) is associated with risk of lung cancer. To clarify this association, we conducted a pooled analysis of CRP and lung cancer risk using data from 20 prospective cohort studies.

Methods: Within the NCI Cohort Consortium, we designed a prospective nested case-control study. Controls were selected from appropriate risk sets and were matched to cases on smoking status, sex, and age at blood draw. This analysis included 5,299 case-control pairs nested within 20 cohorts. Rate ratios (RR) and their 95% confidence intervals associated with a doubling in concentration of CRP were estimated using conditional logistic regression models.

Results: Overall, higher circulating CRP was associated with an increased risk of lung cancer (RR 1.05, 95% CI [1.03, 1.08]). This association varied strongly by smoking status (p-heterogeneity < 0.01), being similar for current (1.09 [1.05, 1.13]) and former smokers (1.09 [1.04, 1.14]), but not for never smokers (0.95 [0.91, 1.00]). The association was strongest for cancers diagnosed less than 2 years after blood draw (1.21 [1.13, 1.29], p-heterogeneity < 0.01), and weakened as time between blood draw and diagnosis increased. The association was similar across all histological subtypes, with the exception of adenocarcinoma for which we observed no association.

Conclusions: CRP is associated with risk of lung cancer. The fact that the association is restricted to ever-smokers, and is most prominent for cancers diagnosed in the first 2 years of follow-up, strongly suggests that CRP is not a causal risk factor, but rather a distal marker of disease.

Citation Format: David C. Muller, Allison M. Hodge, Gianluca Severi, Qiuyin Cai, Klaus Meyer, Kjell Grankvist, Arnulf Langhammer, Paul Brennan, Mattias Johansson, Lung Cancer Cohort Consortium (LC3). C-reactive protein and risk of lung cancer: A pooled analysis of 20 prospective cohorts. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4289.
Abstract 4306: Free IGFBP3 and the risk of liver cancer in a nested case-control study
Authors: Adachi Yasushi , Nojima Masanori , Mori Mitsuru , Matsunaga Yasutaka , Akutsu Noriyuki , Sasaki Shigeru , Endo Takao , Kurozawa Youichi , Wakai Kenji , Tamakoshi Akiko
Published: July 2016

Background: Insulin-like growth factor-1 (IGF1) is a potent mitogen, whereas IGF-binding protein-3 (IGFBP3) binds and inhibits IGF1. High circulating IGF1 and low IGFBP3 are associated with increased risk of several cancers. Here we examined relations of those serum levels with the risk of hepatoma in a prospective case-control study nested in the JACC Study.

Methods: A baseline survey was conducted from 1988 to 1990 and 39,242 subjects donated blood samples. Those who had been diagnosed as hepatoma were regarded as cases for nested case-control studies. Ninety-one cases and 263 controls are eligible for the present analysis. A conditional logistic model was used to estimate odds ratios (OR) for incidence of hepatoma associated with serum IGF1 and IGFBP3 levels.

Results: Both IGF1 and molar ratio of IGF1/IGFBP3 were not correlated with the risk of hepatoma. After adjustment for hepatitis-viral infection, body mass index, smoking, and alcohol intake, higher molar difference of (IGFBP3 - IGF1) was associated with decreased risk of hepatoma (p for trend < 0.001), and peoples in the highest quintile had a lower risk (OR = 0.098; 95%CI = 0.026-0.368). In subgroup analyses, both in male and female, high molar difference of (IGFBP3 - IGF1) was associated with decreased risk of hepatoma (p for trend < 0.001). Both in the elderly and non-elderly, it was correlated inversely with risk of hepatoma (p for trend = 0.001, < 0.001, respectively).

Conclusions: Molar difference of (IGFBP3 - IGF1) might associate inversely with the incidence of hepatoma.

Citation Format: Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Yasutaka Matsunaga, Noriyuki Akutsu, Shigeru Sasaki, Takao Endo, Youichi Kurozawa, Kenji Wakai, Akiko Tamakoshi. Free IGFBP3 and the risk of liver cancer in a nested case-control study. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4306.
Abstract 4316: Pharmacological targeting of the TGF-beta-induced epithelial-mesenchymal transition by anthocyanidins in glioblastoma
Authors: Ouanouki Amira , Muhire Evelyne , Lamy Sylvie , Annabi Borhane
Published: July 2016

Introduction: Glioblastoma multiforme (GBM) is the most common primary brain tumor, known for its invasiveness and high resistance to standard treatments. Therefore, better understanding of the mechanisms that promote mesenchymal changes in GBM are of great clinical importance. Epithelial to mesenchymal transition (EMT) is a reversible biological process in which epithelial cells adopt mesenchymal properties. During EMT, migration, adhesion and cellular morphology are altered allowing benign tumor cells to infiltrate surrounding tissues and to metastasize to distant sites. Several growth factors have been shown to trigger EMT in tumor development; the Transforming Growth Factor-beta (TGF-b) is the most prominent inducer of EMT. Epidemiological studies have shown that diets rich in fruits and vegetables play an important role in preventing cancer due to their polyphenol content. Among polyphenols, the anthocyanidins, found in berries, red grapes, and other pigmented foods, plants and vegetables, have anti-inflammatory, cardioprotective, anti-angiogenic and anti-carcinogenic properties. Despite the well-known role of TGB-b in tumor progression, the impact of anthocyanidins on TGF-b-induced EMT remains misunderstood. Objectives: 1) Characterize the pharmacological effects of anthocyanidins (cyanidin, delphinidin, malvidin, pelargonidin and petunidin) on EMT, 2) identify the molecular targets leading to the inhibition of EMT modulated by anthocyanidins, and 3) characterize their effect on cellular activities involved in this tumor process. Methodology: The human U-87 glioblastoma (U-87 MG) cells were treated with anthocyanidins in pre-, co- and post-treatment with TGF-b. Results: Depending on the treatment, anthocyanidins affect differently the EMT induction by inhibiting U-87 MG cell migration. This inhibition resulted in a down-regulation of mesenchymal markers (fibronectin, snail), phosphorylation of Smad2 proteins and the mitogen-activated protein kinases (ERK, JNK) in a dose-dependent manner. Overall, delphinidin was the most potent inhibitor for all treatments. Conclusion: This study highlights a new antimetastatic action of anthocyanidins that supports the beneficial health and chemopreventive effects of dietary-based strategies against cancer.

Citation Format: Amira Ouanouki, Evelyne Muhire, Sylvie Lamy, Borhane Annabi. Pharmacological targeting of the TGF-beta-induced epithelial-mesenchymal transition by anthocyanidins in glioblastoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4316.
Abstract 4317: Black raspberries show potent activity in prevention of experimental squamous cell esophageal cancer compared to a combination of selective COX-2 and iNOS inhibitors
Authors: Shi Ni , Riedl Kenneth M. , Schwartz Steven J. , Zhang Xiaoli , Steven Steven K. , Chen Tong
Published: July 2016

Esophageal squamous cell carcinoma (SCC) remains a major health threat worldwide and preventive strategies are needed. We previously reported that overexpression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) are correlated with nitrosamine-induced squamous carcinogenesis of the esophagus and the selective iNOS and COX-2 inhibitors significantly inhibit incidence and progression. We also demonstrated anti-cancer activity of black raspberries (BRB) in a rodent model of esophageal SCC. The objective of the current study was to compare the impact of BRB versus the combination of celecoxib, a selective COX-2 inhibitor, and S,S’-1,4-phenylene-bis(1,2-ethanediyl)bis-isothiourea (PBIT), a selective iNOS inhibitor, in inhibition of SCC of the esophagus, and to elucidate molecular mechanism of an effective cancer prevention. We found that BRB is superior to the combination of two drugs in suppression of premalignant tissue growth in the rat esophagi. Moreover, rats fed BRB have lower tumor multiplicity than those fed celcecoxib + PBIT. Our data indicated that BRB also shows a potent inhibitory effect on esophageal iNOS and COX-2, in addition to modulating several associated oncogenic cell signaling pathways. We further conducted parallel mechanistic studies in vitro using BRB anthocyanins and the above two drugs. Our findings demonstrated that dietary BRB is superior to the combination of two chemopreventive pharmaceutical agents in prevention of experimental squamous cell esophageal cancer, suggesting the potential value of additional translational studies in developing food-based products using BRB for the prevention of esophageal SCC carcinogenesis in humans (Supported by NIH/NCI R01 CA131073).

Citation Format: Ni Shi, Kenneth M. Riedl, Steven J. Schwartz, Xiaoli Zhang, Steven K. Steven, Tong Chen. Black raspberries show potent activity in prevention of experimental squamous cell esophageal cancer compared to a combination of selective COX-2 and iNOS inhibitors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4317.
Abstract 432: Loss of MGMT promoter methylation and resistance to cisplatin in non-seminomatous germ cell tumors
Authors: Moutinho Cátia , Garcia-del-Muro Xavier , Guino Elisabet , Vidal August , Puertas Sara , Muñoz Clara , Piulats Josep , Villanueva Alberto , Esteller Manel
Published: July 2016

To explore if MGMT promoter methylation changes have a role in cisplatin chemoresistance, first we study its methylation status in cisplatin sensitive and resistant paired human non-seminomatous germ cancer cell lines. Secondly in xenograft paired tumors and after in human non-seminomatous germ cell primary tumors, from patients treated with cisplatin based chemotherapy. In general we found that cisplatin sensitive samples are related with MGMT promoter hypermethylation associated with its loss of expression. Resistance is present when MGMT promoter is not methylated and expressed. Clinically, the presence of MGMT promoter methylation is related with better overall survival (p = 0.025) in patients with testicular germ cell cancer. Inhibition of MGMT with O6-benzylguanine in vitro or in vivo increases the sensitivity to cisplatin and temozolomide, being this a possible chemotherapeutic approach to re-sensibilize human non-seminomatous germ cell refractory tumors.

Citation Format: Cátia Moutinho, Xavier Garcia-del-Muro, Elisabet Guino, August Vidal, Sara Puertas, Clara Muñoz, Josep Piulats, Alberto Villanueva, Manel Esteller. Loss of MGMT promoter methylation and resistance to cisplatin in non-seminomatous germ cell tumors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 432.
Abstract 4322: Maternal obesity increases tamoxifen resistance in female rat offspring
Authors: Zhang Xiyuan , Cruz Idalia , Zhang Hansheng , Hilakivi-Clarke Leena
Published: July 2016

More than 50% of pregnant women in the USA are overweight or obese, and over 40% gain more weight than recommended by the Institute of Medicine. We investigated if maternal obesity before and during pregnancy affects mammary cancer risk in the offspring, or alters response of the mammary tumors to antiestrogen therapy in a preclinical rat model of estrogen receptor positive (ER+) breast cancer.

Female Sprague-Dawley rats were fed an obesity-inducing high fat (OIHF) or control diet before and during pregnancy. Their offspring were all switched to a control AIN93G diet upon birth. Female offspring of control (n = 35) or OIHF (n = 40) diet fed dams were treated with a carcinogen DMBA on postnatal day 50 to induce ER+ mammary tumors. When mammary tumors reached a size of 13 mm in diameter, 337 ppm TAM citrate was added to the offspring's diet, resulting a daily intake of 15 mg/kg TAM. Responses of the tumors were categorized as de novo resistant (tumor kept growing), partial (size decreased but did not disappear), and complete (tumor disappeared). The animals with complete response were taken off from TAM and monitored for an additional 20 weeks to determine the risk of local recurrence.

The risk of developing mammary tumors was non-significantly increased in the OIHF group. Further, the OIHF exposed offspring had significantly more de novo resistant tumors than the control offspring. Although the percentage of completely responding tumors was similar in the two groups, local recurrence in the OIHF offspring was significantly higher than in the control offspring (90% vs 29%, respectively). To investigate the possible mechanisms of increased recurrence, we measured the protein levels of the members of unfolded protein response (UPR), inflammation and tumor immune pathways. We found that de novo TAM resistant and recurring tumors in the OIHF offspring exhibited significantly increased levels of Perk and Beclin-1, indicating activation of UPR. However, Nbr1 and p62 were also significantly increased in the OIHF offspring, suggestive of inhibition of autophagy in their mammary tumors. The levels of CD8a, a marker of cytotoxic T cells, were significantly reduced, whilst ERα, erBb2/Her2 and Vegfr2 were increased. Changes in the expression of these receptors could indicate increased inflammation.

We conclude that maternal obesity increased TAM resistance and the risk of mammary cancer recurrence in the female offspring. In addition, it induced changes in the UPR, autophagy and tumor immune responses in the offspring's mammary tumors.

Citation Format: Xiyuan Zhang, Idalia Cruz, Hansheng Zhang, Leena Hilakivi-Clarke. Maternal obesity increases tamoxifen resistance in female rat offspring. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4322.
Abstract 4329: The consequence of obesity and obstructive sleep apnea in liver cancer
Authors: Sweeney Nathan W. , Gomes Cecil J. , Pathasarthasy Sairam , Martinez Jesse D.
Published: July 2016

Primary liver cancer is the 3rd leading cause of cancer mortality worldwide. Eighty-five percent of liver cancers is comprised of hepatocellular carcinoma (HCC). Risk of developing HCC increases when patients have obesity related comorbidities, involving non-alcoholic steatohepatitis (NASH), hepatic inflammation, or lipid accumulation. Additionally, obesity is generally regarded as a prime risk factor for the development of obstructive sleep apnea (OSA), a repeated obstruction of the upper airway during sleep leading to oxygen deficiency (OD), which also increases the incidence of NASH. The connection of these morbidities presume that patients suffering from obesity induced OSA have an increased risk of developing HCC. To examine obesity and OSA's role in HCC we combined three generally accepted methods: A one-time injection of tumor initiator diethylnitrosamine followed by continuous administration of the promoter phenobarbital, a high fat diet, and a hypoxia chamber to house the mice for regulation of their oxygen intake, allowing us to mimic the OD seen in OSA. Utilizing these treatment methods and applying microCT imaging to non-invasively and repeatedly monitor the liver, we have been able to examine the effects of obesity and/or OD. Preliminary result indicate that a high fat diet results in obesity, lipidosis and liver damage. Interestingly, OD seems to inhibit obesity while still generating hepatic inflammation. Furthermore, we have observed that obesity and OD together cause severe damage to the liver, enhancing the risk of developing HCC. This study will be a significant preclinical step in distinguishing mechanisms that may explain obesities and OSA's combined consequence in HCC.

Citation Format: Nathan W. Sweeney, Cecil J. Gomes, Sairam Pathasarthasy, Jesse D. Martinez. The consequence of obesity and obstructive sleep apnea in liver cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4329.
Abstract 4331: Discovery of potent 2-Indole-acylsulfonamide Mcl-1 inhibitors using structure guided fragment-based methods
Authors: Shaw Subrata , Tarr James Chris , Pelz Nicholas , Bian Zhiguo , Belmar Johannes , Zhao Bin , Goodwin Craig , Arnold Allison , Sensintaffar John , Rossanese Olivia , Lee Taekyu , Olejniczak Edward , Fesik Stephen
Published: July 2016

Mcl-1 (Myeloid cell leukemia 1), a member of the Bcl-2 family of proteins, is overexpressed and amplified in various cancers and is one of the major acquired resistance mechanisms for many anticancer therapies. Targeting Mcl-1 with small molecules is very challenging because Mcl-1 exerts its effects through protein-protein interactions. Here we describe our continuing efforts in the discovery of potent and selective Mcl-1 inhibitors using fragment-based methods and structure-based design. We previously described the discovery of small-molecule Mcl-1 inhibitors containing a 2-indole-carboxylic core that primarily bind to the P2 pocket. In order to enhance potency, we extend our molecules to occupy the entire BH3 binding interface. A number of P4 site hits were identified using a fragment-based screening while the P2 pocket of Mcl-1 was saturated with our previously reported lead. P4 site ligands were then linked to our initial lead guided by the ternary Mcl-1 structure containing both P2 and P4 units using an acylsulfonamide as a synthetic handle that retained the critical charged-charged interaction with R263. X-ray co-crystal structures of new inhibitors occupying both P2 and P4 sites bound Mcl-1 provided detailed information on how these small-molecules bind to the target and guided subsequent potency optimization. From the efforts, we discovered a novel series of 2-indole-acylsulfonamide containing Mcl-1 inhibitors that exhibit low nanomolar binding affinities to the target and greater than 500-fold selectivity over Bcl-xL. These compounds represent useful starting points for the discovery of clinically useful Mcl-1 inhibitors for the treatment of a wide variety of cancers.

Citation Format: Subrata Shaw, James Chris Tarr, Nicholas Pelz, Zhiguo Bian, Johannes Belmar, Bin Zhao, Craig Goodwin, Allison Arnold, John Sensintaffar, Olivia Rossanese, Taekyu Lee, Edward Olejniczak, Stephen Fesik. Discovery of potent 2-Indole-acylsulfonamide Mcl-1 inhibitors using structure guided fragment-based methods. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4331.
Abstract 4333: Identification and optimization of the first highly selective GLUT-1 inhibitors
Authors: Bauser Marcus , Buchmann Bernd , Siebeneicher Holger , Cleve Arwed , Rehwinkel Hartmut , Neuhaus Roland , Heisler Iring , Mueller Thomas , Kopitz Charlotte Christine
Published: July 2016

Increased glycolysis rates combined with an insufficient cellular respiration in tumor cells have been known for decades as the Warburg effect (1930). One of the key players in this metabolic alteration of cancer cells is glucose transporter 1 (or GLUT-1), which facilitates the transport of glucose across the plasma membranes of mammalian cells. Many tumor biopsies underline the crucial importance of GLUT-1 overexpression for the vitality of many tumor entities. Moreover the glucose uptake dependency of cancer cells can be visualized by the widespread clinical application of 18fluorodeoxyglucose (FDG) uptake in PET tumor imaging. Therefore, inhibition of glucose uptake for the treatment of cancer seems to be an interesting approach.

Based on our first identified GLUT-1 inhibitors (1H-pyrazolo[3,4-d]pyrimidines) with modest selectivity profile, a high throughput screen (HTS) was performed to identify new potent lead structures with unique selectivity against the other members of the GLUT-1 family (GLUT-2,-3 and -4). Among several lead structures we identified from the HTS the quinoline carboxamides with the most promising selectivity profile. Extensive SAR elaboration by synthesizing more than 1600 new derivatives of the lead structure clearly revealed the essential moieties for high activity, potency, and selectivity. Additionally, we were able to improve the in vitro and in vivo PK properties permitting in vivo animal studies. We are able to report for the first time the preclinical profile and structure of the very potent and highly selective GLUT-1 inhibitor BAY-876 representing an ideal tool to further evaluate the scope and limitations of GLUT-1 inhibition as new therapeutic option.

Citation Format: Marcus Bauser, Bernd Buchmann, Holger Siebeneicher, Arwed Cleve, Hartmut Rehwinkel, Roland Neuhaus, Iring Heisler, Thomas Mueller, Charlotte Christine Kopitz. Identification and optimization of the first highly selective GLUT-1 inhibitors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4333.
Abstract 4352: Discovery of the first cell-active inhibitors of poly(ADP Ribose) glycohydrolase through high-throughput screening and computational approaches
Authors: Waszkowycz Bohdan , James Dominic , Durant Steven , Hamilton Nicola , Jones Cliff , Jones Stuart , Jordan Allan , Lau Alan , MGonagle Alison , O’Connor Mark , Smith Kate , Stowell Alex , Tucker Julie , Waddell Ian , Ogilvie Donald
Published: July 2016

DNA repair is a critical process for the survival and normal proliferation of healthy cells. However, given the enhanced levels of cellular stress and genomic instability, these repair processes are even more critical to the survival of malignant cells, where rates of DNA damage are considerably increased. Given this, inhibitors of DNA damage repair have seen a resurgence of interest in recent years in an effort to exploit tumour cell vulnerabilities. One such example of this approach has resulted in the recent approval of the PARP inhibitor olaparib (Lynparza™) for women with advanced ovarian cancer associated with defective BRCA genes.

Olaparib acts against the poly(ADP-ribose)polymerase (PARP) enzymes, more recently re-defined as the ARTD (Diphtheria toxin-like human ADP-ribosyltransferase) enzyme class. Whilst PARP is widely known to play critical and well-understood roles in DNA repair, poly(ADP ribose) glycohydrolase (PARG) is less well known but equally essential for effective DNA repair, degrading PAR chains and facilitating effective DNA repair. However, its inhibition may offer several key advantages over PARP inhibition. Most critically, whilst there are 18 isoforms, there exists only a single PARG protein, offering a specific point of therapeutic intervention. However, due to the open nature of the PARG binding cleft and the nature of the binding site, this protein has been considered to be difficult to inhibit with small, drug-like small molecules, particularly in the cellular context.

This poster will describe our efforts to overcome these challenges against this challenging target and report our early successes achieved through innovative computational chemistry strategies. These efforts have delivered several credible, drug-like startpoints for further medicinal chemistry optimisation.

Citation Format: Bohdan Waszkowycz, Dominic James, Steven Durant, Nicola Hamilton, Cliff Jones, Stuart Jones, Allan Jordan, Alan Lau, Alison MGonagle, Mark O’Connor, Kate Smith, Alex Stowell, Julie Tucker, Ian Waddell, Donald Ogilvie. Discovery of the first cell-active inhibitors of poly(ADP Ribose) glycohydrolase through high-throughput screening and computational approaches. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4352.
Abstract 4362: T cell repertoire diversification is associated with immune related toxicities following immune checkpoint inhibition in metastatic cancer patients
Authors: Oh David Y. , Cham Jason , Zhang Li , Fong Grant , Klinger Mark , Faham Malek , Fong Lawrence
Published: July 2016

Immune checkpoint inhibitors can induce clinical responses to a broad range of tumor types by presumably enhancing T cell responses against the tumor. These treatments are also associated with certain side effects that are also thought to be immune mediated (termed immune-related adverse events, or IRAEs). The mechanism by which IRAEs occur, and biomarkers that may predict IRAE development, are unknown. In prior work (Cha et al. Sci Transl Med 2014), we demonstrated that treating metastatic cancer patients with checkpoint inhibitors blocking CTLA-4 can lead to T cell repertoire diversification. However, we found that prolonged survival was not associated with the induction of high frequency clonotypes, but rather the maintenance of a pre-existing T cell response. Here, we examined whether treatment-induced TCR diversification is related to another clinical outcome: the development of IRAEs. We find that IRAEs are specifically associated with a more diverse T cell repertoire and with an increase in the number of T cell clonotypes, including the generation of de novo clones. This broadening of the circulating T cell repertoire occurred early with treatment, preceding the development of IRAEs. While IRAE patients demonstrate markedly greater diversity in their CD4+ T cells, they demonstrate a greater degree of change in clonal frequencies in their CD8+ T cells after ipilimumab, which may have key implications in the pathogenic mechanism of IRAE development. Finally, clinical response to checkpoint blockade is also associated with increased diversity. These results indicate that immune repertoire diversity following immune checkpoint inhibition can be both detrimental and beneficial to patients with metastatic cancer.

Citation Format: David Y. Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong. T cell repertoire diversification is associated with immune related toxicities following immune checkpoint inhibition in metastatic cancer patients. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4362.
Abstract 4368: High-throughput phenotyping of lung cancer somatic mutations
Authors: Berger Alice H. , Brooks Angela N. , Wu Xiaoyun , Shrestha Yashaswi , Chouinard Candace , Piccioni Federica , Bagul Mukta , Kamburov Atanas , Imielinski Marcin , Hogstrom Larson , Zhu Cong , Yang Xiaoping , Pantel Sasha , Sakai Ryo , Kaplan Nathan , Root David , Narayan Rajiv , Natoli Ted , Lahr David , Tirosh Itay , Tamayo Pablo , Getz Gad , Wong Bang , Doench John , Subramanian Aravind , Golub Todd R. , Meyerson Matthew , Boehm Jesse S.
Published: July 2016

Recent cancer genome sequencing and analysis has identified millions of somatic mutations in cancer. However, the functional impact of most variants is poorly understood, limiting the use of this genetic knowledge for clinical decision-making. Here we describe a new high-throughput approach, expression-based variant impact phenotyping (eVIP), which uses gene expression changes to infer somatic mutation impact. We generated a lentiviral expression library representing 53 genes and 194 somatic mutations identified in primary lung adenocarcinomas. Next, we introduced this library into A549 lung adenocarcinoma cells and 96 hours later performed gene expression profiling using Luminex-based L1000 profiling. We built a computational pipeline, eVIP, to compare mutant and wild-type expression signatures to infer whether variants were gain-of-function, change-of-function, loss-of-function, or neutral. Overall, eVIP identified 69% of mutations as impactful whereas 31% appeared functionally neutral. A very high rate, 92%, of missense mutations in the KEAP1 and STK11 tumor suppressor genes were found to inactivate or diminish protein function. As a complementary approach, we assessed which mutations are epistatic to EGFR or capable of initiating xenograft tumor formation in vivo. A subset of the impactful mutations identified by eVIP could induce xenograft tumor formation in mice and/or confer resistance to cellular EGFR inhibition. Among these mutations were 20 rare or non-canonical somatic variants in clinically-actionable or -relevant oncogenes including EGFR S645C, ARAF S214C and S214F, ERBB2 S418T, and PIK3CA E600K. eVIP can, in principle, characterize any genetic variant, independent of prior knowledge of gene function. Further application of eVIP should significantly advance the pace of functional characterization of mutations identified from genome sequencing.

Citation Format: Alice H. Berger, Angela N. Brooks, Xiaoyun Wu, Yashaswi Shrestha, Candace Chouinard, Federica Piccioni, Mukta Bagul, Atanas Kamburov, Marcin Imielinski, Larson Hogstrom, Cong Zhu, Xiaoping Yang, Sasha Pantel, Ryo Sakai, Nathan Kaplan, David Root, Rajiv Narayan, Ted Natoli, David Lahr, Itay Tirosh, Pablo Tamayo, Gad Getz, Bang Wong, John Doench, Aravind Subramanian, Todd R. Golub, Matthew Meyerson, Jesse S. Boehm. High-throughput phenotyping of lung cancer somatic mutations. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4368.
Abstract 4372: MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism
Authors: Ramkissoon Lori , Bandopadhayay Pratiti , Jain Payal , Bergthold Guillaume , Resnick Adam , Beroukhim Rameen , Ligon Keith
Published: July 2016

Diffuse pediatric low-grade gliomas (PLGGs) are among the most common solid tumors in children. While BRAF mutations and MYBL1 rearrangements have recently been identified as diagnostic and treatment related oncogenic drivers in pediatric gangliogliomas and diffuse astrocytomas, respectively, for the majority of diffuse PLGGs the oncogenic driver(s) remain unknown. Recent efforts to identify new oncogenic drivers lack sufficient power to determine the true frequency of alterations in genes or to associate specific alterations with rare histological subtypes, such as Angiocentric gliomas (AGs). To address this issue, we performed genomic analysis of new and published data from 249 PLGGs including 19 AGs. We identified MYB-QKI fusions as a specific, recurrent, single candidate driver event in AGs. Although MYB is expressed during early brain development in a subset of progenitor cells, it is not known to play a role in normal cortical brain where AGs frequently occur. In vitro functional studies show MYB-QKI rearrangements promote tumorigenesis in mouse neural stem cells (mNSCs) through three mechanisms: MYB activation by truncation, enhancer translocation driving aberrant MYB-QKI expression, and hemizygous loss of the tumor suppressor QKI. Expression of the MYB-QKI fusion increases mNSC proliferation and activates known MYB target genes including KIT and CDK6. H3K27ac enhancer profiling of AG tumors demonstrate active enhancer elements are translocated proximally to the MYB promoter while in vitro promoter assays confirmed that QKI enhancer sequences activate the MYB promoter. Together with functional studies demonstrating that MYB-QKI can also bind and activate the MYB promoter, these data support a positive auto-regulatory feed-back loop model in which active MYB-QKI is able to drive its own expression through enhanced MYB-promoter-activation. Furthermore, when injected orthotopically into immunodeficient mice, expression of truncated MYB or MYB-QKI is sufficient to induce tumor formation that recapitulate histologic and immunophenotypic characteristics of AGs. Analysis of AG specific MYB-QKI fusion represents the first example of how a single driver rearrangement simultaneously transforms cells via three genetic and epigenetic mechanisms in a cancer.

Citation Format: Lori Ramkissoon, Pratiti Bandopadhayay, Payal Jain, Guillaume Bergthold, Adam Resnick, Rameen Beroukhim, Keith Ligon. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4372.
Abstract 4379: Exosomes isolated from ovarian cancer cells transfer oncogenic features to the target cells promoting epithelial to mesenchymal transition
Authors: Kobayashi Miharu , Cohelo Laura , Guanzon Dominic , Scholz-Romero Katherin , Brown Melissa , Kline Richard , Li Li , Rice Gregory , Salomon Carlos
Published: July 2016

Introduction: Recent studies establish the role of exosomes in cell-cell communication in cancer. As adaptation to hypoxia is a critical step in tumor progression, the aim of this study was to test the hypotheses that hypoxia promotes epithelial to mesenchymal transition (EMT) and that exosomes isolated from hypoxic cancer cells transfer oncogenic properties to target cells.

Methods: CaOV-3 cell line was used as model of ovarian cancer. Cells were cultured under 8% O2 (normoxia) and 1% O2 (hypoxia) for 48 hours. Exosomes were isolated from cell-conditioned media by differential and buoyant density centrifugation. Exosomes were characterised by the presence of TSG101 using Western Blot, size distribution (Nanosight™) and morphology by electron microscopy. Exosomal protein and miRNA content were determined using liquid chromatography mass spectrometry (5600 Triple TOF, AB Sciex,) and an Illumina NextSeq 500 Platform, respectively. The effects of exosomes released from CaOV-3 incubated under 1% O2 on EMT induction in CaOV-3 cells cultured under 8% O2 were assessed by the measuring the ratio of E-cadherin (epithelial marker) to N-cadherin (mesenchymal marker) by Wester Blot and the expression of 84 key genes involve in the EMT (RT2 Profiler™ PCR Array, QIAGEN).

Results: Exosomes were identified as spherical vesicles with a typical cup-shape, diameters ranging from 50 to 100 nm with the expression of TSG101. Exosome release from ovarian cancer cells was ∼4-fold higher under hypoxic than normoxic conditions (p <0.001). Hypoxia-specific exosomal proteins and miRNAs were identified. Hypoxia induced EMT (increased N-cadherin/E-cadherin ratio) on CaOV-3 cells compared to cells cultured under 8% O2. Interestingly, exosomes isolated from hypoxic conditions mimic the effect of hypoxia on cells cultured under 8% O2, involving the unregulated of a set of transcription factors associated with EMT such as SNAIL1/SNAIL2, bHLH (E47, E2-2, and TWIST1/TWIST2), and ZEB1/ZEB2.

Conclusion: The data obtained is consistent with the hypothesis that exosomes released from cancer cells modify the phenotype of target cells by transferring pro-oncogenic molecules inducing cancerous phenotype of receipt cells, contributing to tumour growth and metastasis.

Citation Format: Miharu Kobayashi, Laura Cohelo, Dominic Guanzon, Katherin Scholz-Romero, Melissa Brown, Richard Kline, Li Li, Gregory Rice, Carlos Salomon. Exosomes isolated from ovarian cancer cells transfer oncogenic features to the target cells promoting epithelial to mesenchymal transition. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4379.
Abstract 438: Development of an autoantibody panel that reflects disease pathogenesis in ovarian cancer
Authors: Kobayashi Makoto , Boldt Clayton R. , Yang Wei-Lei , Aguilar-Bonavides Clemente , Wang Hong , Lu Zhen , Bast Robert C. , Hanash Samir M.
Published: July 2016

Introduction

The serous subtype of ovarian cancer is responsible for most ovarian cancer deaths. When patients are diagnosed with early stage disease localized to the ovary or pelvis, current therapies can achieve survival rates up to 75-90%. However, approximately 70% of cases are diagnosed at an advanced stage, with a 5-year survival rate of less than 20%. A strategy based on autoantibodies which occur early during tumor development has merit for early cancer detection. We have applied a combined approach of mass spectrometry of circulating antigen-antibody complexes and with high-density protein microarrays to develop ovarian cancer serum markers based on autoantibody reactivity.

Materials and methods

Serum samples were obtained from women diagnosed with ovarian cancer (cases) and healthy controls undergoing ovarian cancer screening, women undergoing gynecologic surgery for various conditions but with normal ovarian pathology (surgical controls), and women without malignancy but with benign ovarian disease (benign controls). All samples were obtained following Institutional Review Board approval and informed consent. For autoantibody analysis, we used recombinant protein arrays containing 5,005 recombinants arrayed in duplicate and Alexa 647-labeled anti-human IgG were purchased from Invitrogen. Circulating Immunoglobulin (Ig) bound antigen analysis was performed using LC-MS/MS.

Results

Autoantibodies against 20 targets were identified in ovarian cancer patients compared to healthy, surgical and benign controls by protein array analysis with P<0.01. Ingenuity Pathway Analysis of these 20 antigens, exhibited major nodes of p53, MYC, and ESR1 associated networks reflecting ovarian cancer pathogenesis. Concordant findings were observed with LC-MS/MS analysis of Ig-antigen complexes.

Conclusion

We have uncovered a set of 20 protein antigens associated with the development of autoantibodies in ovarian cancer that reflect disease pathogenesis and that have potential relevance for early detection.

Citation Format: Makoto Kobayashi, Clayton R. Boldt, Wei-Lei Yang, Clemente Aguilar-Bonavides, Hong Wang, Zhen Lu, Robert C. Bast, Samir M. Hanash. Development of an autoantibody panel that reflects disease pathogenesis in ovarian cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 438.